The antitumor effect of high-dose chemotherapy (HDC) followed by autologous peripheral blood stem cell transplantation (auto-PBSCT) is considered superior to that of conventional chemotherapy. However, the long-term benefits of this strategy in Japan remain unclear.Therefore, in this study, 109 cancer patients enrolled between 1989 and 1999 were treated with HDC and auto-PBSCT. Patients were evaluated for long-term survival and late-onset complications, including secondary malignancy. The mean number of CD34+ cells harvested per apheresis was larger in the group receiving high-dose cytosine arabinoside or high-dose etoposide plus granulocyte colony-stimulating factor (G-CSF) than in the group receiving conventional chemotherapy plus G-CSF. The 5-year overall survival rates for non-Hodgkin’s lymphoma patients in first complete remission (CR) (83.2%), second or subsequent CR (74.1%), or first partial remission (PR) (66.7%) at the time of transplantation were significantly higher than those with no remission (35.7%) at the time of transplantation (first CR,P < .05; second or subsequent CR,P < .05; first PR,P < .05). The 5-year overall survival (OS) rates for breast cancer was 40.8%, and the disease-free survival rate was extremely low (8.8%). The 5-year OS rates for chemotherapy-sensitive and chemotherapy-resistant diseases at the time of transplantation were 32.7% and 35.7%, respectively, a difference that was not considered significant. The 5-year OS for germ cell tumor was 80.0%, and the disease-free survival rate was 77.9%. The rate of therapy-related death was 8.2%. The occurrence rate of secondary malignancy was 0.9%. Late-onset complications were observed in 4 cases (glomerulonephritis, interstitial pneumonitis, ulcerative colitis, and acute myelogenous leukemia). At 3.7%, the occurrence rate was not very high, but most complications of auto-PBSCT were life threatening and interfered with patients’ quality of life. A careful follow-up is required for at least 2 years after transplantation, because the mean occurrence time of late-onset complications is 16.7 months posttransplantation.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Majolino I, Pearce R, Taghipour G, Goldstone AH. Peripheral-blood stem-cell transplantation versus autologous bone marrow transplantation in Hodgkin’s and non-Hodgkin’s lymphomas: a new matched-pair analysis of the European Group for Blood and Marrow Transplantation Registry data.J Clin Oncol. 1997;15:509–517.
Shipp MA, Abeloff MD, Antman KH, et al. International Consensus Conference on High-Dose Therapy with Hematopoietic Stem Cell Transplantation in Aggressive Non-Hodgkin’s Lymphomas: report of the jury.J Clin Oncol. 1999;17:423–429.
Rutgers EG, Richel DJ, Baars JW, et al. Preliminary analysis of a randomized phase II study of high-dose chemotherapy in high-risk breast cancer [abstract].Eur J Cancer. 1996;32A:5.
Peters WP, Jones RB, Vredenburgh J, et al. A large, prospective, randomized trial of high-dose combination alkylating agents (CPB) with autologous cellular support (ABMS) as consolidation for patients with metastatic breast cancer achieving complete remission after intensive doxorubicin-based induction therapy (AFM).Proc Am Soc Clin Oncol. 1996;15:121–129.
Rahman ZU, Frye DK, Smith TL, et al. Results and long term follow-up for 1581 patients with metastatic breast carcinoma treated with standard dose doxorubicin-containing chemotherapy: a reference.Cancer. 1999;85:104–111.
Gianni AM, Bregni M, Siena S, et al. High dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma.N Engl J Med. 1997;336:1290–1297.
Arriagada R, Le Chevalier T, Pignon JP, et al. Initial chemotherapeutic doses and survival in patients with limited small-cell lung cancer.N Engl J Med. 1993;329:1848–1852.
Makino S, Harada M, Akashi K, et al. A simplified method for cryopreservation of peripheral blood stem cells at −80 degrees C without rate-controlled freezing.Bone Marrow Transplant. 1991;8:239–244.
Chou T, Ishiguro T, Imajo K, et al. A multicenter early phase II study of high-dose chemotherapy with autologous peripheral blood stem cell transplantation for treatment of intermediate-grade non-Hodgkin’s lymphoma.Jpn J Clin Hematol. 1999;40:1058–1067.
Lotz JP, Machover D, Dalassagne B, et al. Phase I-II study of two consecutive courses of high-dose epipodophyllotoxin, ifosfamide, and carboplatin with autologous bone marrow transplantation for treatment of adult patients with solid tumors.J Clin Oncol. 1991;9:1860–1870.
Wilson WH, Jain V, Bryant G, et al. Phase I and II study of high-dose ifosfamide, calboplatin, and etoposide with autologous bone marrow rescue in lymphomas and solid tumors.J Clin Oncol. 1992;10:1712–1722.
Myers SE, Mick R, Williams SF. High-dose chemotherapy with autologous stem cell rescue in women with metastatic breast cancer with involved bone marrow: a role for peripheral blood progenitor transplant.Bone Marrow Transplant. 1994;13:449–454.
Kusnierz-Glaz CR, Schlegel PG, Wona RM, et al. Influence of age on the outcome of 500 autologous bone marrow transplant procedures for hematological malignancies.J Clin Oncol. 1997;15:18–25.
Andre M, Henry-Amar M, Blaise D, et al. Incidence of second cancers and causes of death after autologous stem cell transplantation for Hodgkin’s disease [abstract].Blood. 1995;86(suppl 1):640a.
To LB, Davy MLJ, Haylock DN, et al. Auto-transplantation using peripheral blood stem cells mobilized by cyclophosphamide.Bone Marrow Transplant. 1989;4:595–596.
Takaue Y, Hoshi Y, Watanabe T, et al. Collection and auto-grafts of peripheral blood stem cells in children with acute leukemias or non-Hodgkin’s lymphoma.Int J Cell Cloning. 1992;10(suppl 1): 152–154.
Gianni AM, Siena S, Bregni M, et al. Granulocyte-macrophage colony-stimulating factor to harvest circulating haemopoietic stem cells for auto-transplantation.Lancet. 1989;2:580–585.
Sheridan WP, Begley CG, Juttner CA, et al. Effect of peripheralblood progenitor cells mobilized by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy.Lancet. 1992;339:640–644.
Siena S, Bregni M, Brando B, et al. Circulation of CD34+, hematopoietic stem cells in the peripheral blood of high-dose cyclophosphamide-treated patients: enhancement by intravenous recombinant human granulocyte-macrophage colony-stimulating factor.Blood. 1989;74:1905–1914.
Shimazuki C, Oku N, Ashihara E, et al. Collection of peripheral blood stem cells mobilized by high-dose Ara-C plus VP-16 or aclarubicin followed by recombinant human granulocyte-colony stimulating factor.Bone Marrow Transplant. 1992;10:341–346.
A predictive model for aggressive non-Hodgkin’s lymphoma. The International Non-Hodgkin’s Lymphoma Prognostic Factor Project.N Engl J Med. 1993;329:987–994.
Haioun C, Lepage E, Gisselbrecht C, et al. Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor risk aggressive non-Hodgkin’s lymphoma: update results of the prospective study LNH 87-2.J Clin Oncol. 1997;15:1131–1137.
Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma.N Engl J Med. 1995;333:1540–1545.
Nademanee A, Molina A, O’Donnell MR, et al. Results of high-dose therapy and autologous bone marrow/stem cell transplantation during remission in poor-risk intermediate and high-grade lymphoma: international index high and high-intermediate risk group.Blood. 1997;90:3844–3852.
Peter WP, Ross M, Vredenburg JJ, et al. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk breast cancer.J Clin Oncol. 1993;11:1132–1143.
Rodenhuis SR, Richel DJ, van der Wall E, et al. Randomized trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement.Lancet. 1998;352:51–52.
Long GD, Negrin RS, Hoyle CF, et al. Multiple cycles of high dose chemotherapy supported by hematopoietic progenitor cells as treatment for patients with advanced malignancies.Cancer. 1995;76:860–868.
Stone RM, Neuberg D, Soffier R, et al. Myelodysplastic syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkin’s lymphoma.J Clin Oncol. 1994;12:2535–2543.
Darrington DL, Vose JM, Anderson FR, et al. Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem cell transplantation for lymphoid malignancies.J Clin Oncol. 1994;12:2527–2534.
Anonymous:WHO Handbook for Reporting Results of Cancer Treatment. Geneva: World Health Organization;1979:14–21.
About this article
Cite this article
Kohda, K., Sakamaki, S., Matsunaga, T. et al. Long-Term Survival and Late-Onset Complications of Cancer Patients Treated With High-Dose Chemotherapy Followed by Autologous Peripheral Blood Stem Cell Transplantation. Int J Hematol 73, 251–257 (2001). https://doi.org/10.1007/BF02981946
- High-dose chemotherapy
- Secondary malignancy
- Solid tumor